The price that didn't move

In January 2021 France reimbursed apixaban at €62.88 a box. In April 2026, after the molecule's patent cliff had reshaped prices across Europe, the figure was €59.16. Every month in between sits within a few centimes of €59.1: a flat line drawn through the most dramatic pricing event in the molecule's history.

That flat line is not an accident or an oversight. It is what an administered pricing system looks like in monthly data, and it is the fourth system signature we have documented for this one molecule.

One cut, by decree

The only movement in the French series is a step from €62.6 to €59.2 across February and March 2022: a routine administered price revision agreed with CEPS, the pricing committee, years before any generic pressure existed. After that, nothing. Not when England's generics arrived in mid-2023. Not when England's price fell 95%. Not when Medicare's negotiated price cut the US figure by 43% in January 2026.

France's machinery simply does not transmit those signals. Prices move when CEPS and the framework agreement say they move: by revision, by clawback, by convention. Whatever held elsewhere, the French list price held at €59.1.

The bill doubled anyway

Flat prices with growing use have arithmetic consequences. French apixaban volumes rose from about 720,000 boxes a month in early 2021 to 1.42 million by spring 2026, a near doubling. With the price pinned, the monthly reimbursement base rose from roughly €45m to €84m, up 86%.

England ran the same experiment with the opposite pricing system. Its volumes also grew, by 17%. Its monthly bill fell 88%, from £34m to £2m, because the price collapsed underneath the growth. Two health systems, the same drug, the same five years: one bill nearly doubled, the other nearly vanished.

Why the machine matters for forecasts

A loss-of-exclusivity assumption borrowed from one market is meaningless in another. Modelling France with a UK-style erosion curve would have overstated savings by nearly the entire French bill; modelling England with French inertia would have missed a 95% collapse. The erosion parameter belongs to the system, not the molecule.

France's system is documented on our French market pathway: ASMR-anchored pricing through CEPS, savings requirements for me-too listings, and revision by agreement rather than by competition. This article is what that pathway looks like when it meets 64 months of real reimbursement data.

Every figure here comes from public sources: France's Medic'AM reimbursement files and England's prescribing dataset, both processed in our data lake and checkable end to end.